Pseudomonas aeruginosa
Ontology highlight
ABSTRACT:
REPOSITORIES: ENA
Similar Datasets
Project description:Detection of VIM type-producing multidrug-resistant Pseudomonas aeruginosa in Japan
| PRJDB8977 | ENA
Project description:Detection of GES-5-producing multidrug-resistant Pseudomonas aeruginosa in Japan
| PRJDB6635 | ENA
Project description:Detection of GES-5-producing multidrug-resistant Pseudomonas aeruginosa in Japan
| PRJDB4746 | ENA
Project description:VIM-2 and OXA-4 co-producing Pseudomonas aeruginosa
| PRJNA634848 | ENA
Project description:Multidrug-resistant Pseudomonas aeruginosa clinical isolates in Myanmar
| PRJDB6612 | ENA
Project description:Methylrhodomelol (1) is a bromophenol from the red alga Vertebrata lanosa (L.) T.A.Christensen that has been associated with antimicrobial properties. Aim of the current study was therefore, to assess the antimicrobial potential of this compound in more detail against the gram-negative pathogen Pseudomonas aeruginosa. 1 exerted weak bacteriostatic activity against different strains when grown in minimal medium, whereas other phenolics were inactive. In addition, 1 (35 and 10 µg/mL) markedly enhanced the susceptibility of multidrug resistant P. aeruginosa towards the aminoglycoside gentamicin, while it did not affect the viability of Vero kidney cells up to 100 µM. Finally, pyoverdine release was reduced in bacteria treated at sub-inhibitory concentration, but no effect on other virulence factors was observed. Transcriptome analysis of treated versus untreated P. aeruginosa indicated an interference of 1 with bacterial carbon and energy metabolism, which was corroborated by RT-qPCR and decreased ATP-levels in treated bacteria.
2024-04-07 | GSE249483 | GEO
Project description:Multidrug-resistant epidemic Pseudomonas aeruginosa genome sequencing (early isolate)
| PRJNA224149 | ENA
Project description:Multidrug-resistant epidemic Pseudomonas aeruginosa genome sequencing (late isolate)
| PRJNA224150 | ENA
Project description:Epidemiological study on multidrug-resistant Pseudomonas aeruginosa clinical isolates in Vietnam
| PRJDB4025 | ENA
Project description:Circumventing or overwhelming the bacterial adaptation capabilities is key to combatting multidrug-resistant pathogens like Pseudomonas aeruginosa. In an effort to understand the physiological response of P. aeruginosa to clinically relevant antibiotics, we investigated the proteome after exposure to ciprofloxacin, levofloxacin, rifampicin, gentamicin, tobramycin, azithromycin, tigecycline, polymyxin B, colistin, ceftazidime, meropenem, and piperacillin/tazobactam. We further investigated the response to CHIR-90, which represents a promising class of lipopolysaccharide biosynthesis inhibitors currently under evaluation. Radioactive pulse-labeling of newly synthesized proteins followed by 2D-PAGE was used to monitor the acute response of P. aeruginosa to antibiotic treatment. Marker proteins were excised from non-radioactive gels and identified by mass spectrometry. The proteomic profiles provide insights into the cellular defense strategies for each antibiotic. A mathematical comparison of these response profiles based on upregulated marker proteins revealed similarities of responses to antibiotics acting on the same target area.
2021-11-29 | PXD029948 | Pride